aTyr Pharma Announces Second Quarter 2019 Results and Provides Corporate Update
August 14, 2019 08:00 ET
|
aTyr Pharma, Inc.
aTyr to report interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients in Q4 2019 Company to host conference call and webcast today, August...
aTyr Pharma to Announce Second Quarter 2019 Results on August 14th
August 07, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
Leading Immunobiology Researcher Dr. David Briscoe Joins aTyr Pharma as Scientific Advisor
August 06, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines, today announced the...
aTyr Pharma to Host Key Opinion Leader Call and Webcast on Sarcoidosis and the Current Treatment Landscape
July 10, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, July 10, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Strengthens Board of Directors with the Appointment of Two New Members
July 01, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, July 01, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Reverse Stock Split to Regain NASDAQ Compliance
June 28, 2019 16:05 ET
|
aTyr Pharma, Inc.
SAN DIEGO, June 28, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces First Quarter 2019 Results and Provides Corporate Update
May 13, 2019 16:05 ET
|
aTyr Pharma, Inc.
Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients ongoing Advanced lead position in Neuropilin-2 (NRP-2) biology with inaugural NRP-2 summit Company to host...
aTyr Pharma to Announce First Quarter 2019 Results on May 13th
May 06, 2019 16:58 ET
|
aTyr Pharma, Inc.
SAN DIEGO, May 06, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma to Host Inaugural Summit Meeting on Neuropilin-2 (NRP-2) Biology
April 16, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, April 16, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma Announces $5 Million Registered Direct Offering led by The Federated Kaufmann Small Cap Fund
April 11, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, April 11, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...